Literature DB >> 32535691

Feasibility and optimization of ultra-short echo time MRI for improved imaging of IVC-filters at 3.0 T.

Gesine Knobloch1, Scott Nagle1,2,3, Timothy Colgan1, Tilman Schubert1,4, Kevin M Johnson1,2, Peter Bannas1,5, Geng Li6, Louis Hinshaw1, James Holmes1, Scott B Reeder7,8,9,10,11.   

Abstract

PURPOSE: To determine the feasibility of ultra-short echo time (UTE) MRA for assessment of inferior vena cava (IVC) filters and evaluate the impact of different imaging protocols at 3.0 T, using conventional Cartesian MRA (cMRA) as the reference standard.
METHODS: Patients with IVC-filters were recruited for this prospective IRB-approved, HIPAA-compliant study. Subjects underwent contrast-enhanced breath-held and a free-breathing 3D radial acquisition UTE-MRA (bhUTE, fbUTE) at three different flip angles (FA: 10°, 15°, 20°) to optimize T1-weighted image quality. Two radiologists performed a direct comparison consensus reading to assess the optimal FA. Image quality (IQ) of both UTE techniques at the best FA was rated independently on a 4-point Likert scale (0 = non-diagnostic, 3 = excellent) and compared to 3D T1-weighted breath-held cMRA.
RESULTS: Nine subjects were recruited. Low FAs of 10° were rated best for both UTE techniques. fbUTE was excellent (3, IQR: 2; 3) and significantly better for IVC-filter depiction than cMRA (2, IQR: 0.75; 2, p = 0.001) and bhUTE (1.5, IQR: 0.75; 2, p < 0.001). Both UTE techniques showed significantly less filter-related artifacts (fbUTE: 28%, bhUTE: 33%) than cMRA (89%, p = 0.001 and p = 0.002, respectively). However, IQ of bhUTE was generally degraded due to high image noise and low image contrast. IQ of the IVC venogram was best with cMRA. Clinically relevant signal voids were only observed with the cage-shaped OptEase filter.
CONCLUSION: UTE-MRA is feasible at 3.0 T for the assessment of IVC-filters, particularly using a free-breathing protocol. Larger studies are needed to investigate the clinical utility of free-breathing UTE-MRA for assessment of IVC-filter-related complications.

Entities:  

Keywords:  Feasibility studies; Magnetic resonance angiography; Prospective studies; Vena cava filters; Vena cava, inferior

Year:  2021        PMID: 32535691      PMCID: PMC8167878          DOI: 10.1007/s00261-020-02548-w

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  16 in total

1.  Improved lumen visualization in metallic vascular implants by reducing RF artifacts.

Authors:  Lambertus W Bartels; Chris J G Bakker; Max A Viergever
Journal:  Magn Reson Med       Date:  2002-01       Impact factor: 4.668

Review 2.  Inferior vena cava filters.

Authors:  L Duffett; M Carrier
Journal:  J Thromb Haemost       Date:  2016-12-26       Impact factor: 5.824

3.  FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.

Authors:  Min Lu; Martin H Cohen; Dwaine Rieves; Richard Pazdur
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

4.  The Simon nitinol filter: evaluation by MR and ultrasound.

Authors:  D Kim; R R Edelman; C J Margolin; D H Porter; C R McArdle; B W Schlam; L E Gianturco; J B Siegel; M Simon
Journal:  Angiology       Date:  1992-07       Impact factor: 3.619

5.  Relaxivity of Ferumoxytol at 1.5 T and 3.0 T.

Authors:  Gesine Knobloch; Timothy Colgan; Curtis N Wiens; Xiaoke Wang; Tilman Schubert; Diego Hernando; Samir D Sharma; Scott B Reeder
Journal:  Invest Radiol       Date:  2018-05       Impact factor: 6.016

6.  Management of the thrombosed filter-bearing inferior vena cava.

Authors:  Onur Sildiroglu; Harun Ozer; Ulku Cenk Turba
Journal:  Semin Intervent Radiol       Date:  2012-03       Impact factor: 1.513

7.  Optimized 3D ultrashort echo time pulmonary MRI.

Authors:  Kevin M Johnson; Sean B Fain; Mark L Schiebler; Scott Nagle
Journal:  Magn Reson Med       Date:  2012-12-04       Impact factor: 4.668

8.  Ferumoxytol for treating iron deficiency anemia in CKD.

Authors:  Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

9.  4D flow image quality with blood pool contrast: a comparison of gadofosveset trisodium and ferumoxytol.

Authors:  Kanae Mukai; Nicholas S Burris; Vaikom S Mahadevan; Elyse D Foster; Karen G Ordovas; Michael D Hope
Journal:  Int J Cardiovasc Imaging       Date:  2017-09-08       Impact factor: 2.357

Review 10.  Emerging applications for ferumoxytol as a contrast agent in MRI.

Authors:  Mustafa R Bashir; Lubna Bhatti; Daniele Marin; Rendon C Nelson
Journal:  J Magn Reson Imaging       Date:  2014-06-30       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.